Evidence map›Paper›PMID 36073517›Full record

Trial reportHaematologica2023

Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial.

Grégoire Stalder, Madeleine Suffiotti, Amandine Segot, Alessandra Noto, Giuseppe Pantaleo, Olivier Spertini, Michel Obeid

Open access · goldAbstract readClinical TrialLetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Grégoire StalderService and Central Laboratory of Hematology, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne, Switzerland; Service of Hematology and Laboratory of Hematology, Institut Central des Hôpitaux, Hôpital du Valais, Av. du Grand-Champsec 86, CH-1951 Sion, Switzerland; University of Lausanne, Lausanne.
Madeleine SuffiottiDivision of Immunology and Allergy, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne.
Amandine SegotService and Central Laboratory of Hematology, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne.
Alessandra NotoDivision of Immunology and Allergy, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne.
Giuseppe PantaleoUniversity of Lausanne, Lausanne, Switzerland; Division of Immunology and Allergy, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne.
Olivier SpertiniService and Central Laboratory of Hematology, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne, Switzerland; University of Lausanne, Lausanne.
Michel ObeidUniversity of Lausanne, Lausanne, Switzerland; Division of Immunology and Allergy, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne. michel.obeid@chuv.ch.
University of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Myeloid, AcuteLymphohistiocytosis, HemophagocyticAdultClinical Trials as TopicDexamethasoneEtoposideHumansNitrilesPilot ProjectsPyrazolesPyrimidinesDexamethasoneEtoposideNitrilesPyrazolesPyrimidinesruxolitinib

Identifiers

PMID36073517
PMCPMC9827158
OpenAlexW4294992651

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.